Clinical Trial Update: Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates the efficacy and safety of nilotinib (AMN107) in patients with gastrointestinal stromal tumors who have failed both imatinib and su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: COMPLETED | Results posted: 2011-05-17